Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury

Mondello, Stefania; Gabrielli, A.; Catani, Sheila; D’Ippolito, Mariagrazia; Jeromin, Andreas; Ciaramella, Antonio; Bossù, Paola; Schmid, Kara; Tortella, Frank C.; Wang, Kevin; Hayes, Ronald L.; Formisano, Rita

doi:10.3109/02699052.2012.700083

Cited by 54 publications

(43 citation statements)

References 33 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower BDNF values are associated with worse prognosis, whereas with other TBI biomarkers, lower values are typically associated with better prognosis, 4 with the exception of microtubule-associated protein 2, a dendritic marker, which has higher values at 6 months after injury in severe TBI subjects with improved outcomes. 3 We postulate that during the acute phase of TBI, the formation of new neuronal circuits might not be advisable, and therefore there may be no need for increased production of neurotrophic factors. However, it is possible that the initial decrease in circulating BDNF during the acute phase of trauma (as seen in our study) is potentially followed by a subsequent increase, especially during the sub-acute/chronic phases of TBI.…”

Section: Diagnostic and Prognostic Value Of Bdnf In Tbimentioning

confidence: 99%

“…A number of candidate circulating TBI biomarkers have shown promise for aiding in the diagnosis of TBI and in identifying patients with traumatic abnormalities on head computed tomography (CT) scan. [1][2][3][4] Importantly, their ability to predict adverse consequences of TBI has been limited. Objective diagnosis and prognosis of TBI will help improve triaging to appropriate medical care at time of injury, guide judicious use of neuroimaging, and inform the development of ''return to work or play'' guidelines.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury

Korley

Yue

et al. 2016

Journal of Neurotrauma

115

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration. We investigated the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI). We examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments (EDs) of the Johns Hopkins Hospital ( JHH; n = 76) and San Francisco General Hospital (SFGH, n = 80), and a control group of JHH ED patients without TBI (n = 150). Findings were subsequently validated in the prospective, multi-center Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Pilot study (n = 159). We investigated the association between BDNF, glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) and recovery from TBI at 6 months in the TRACK-TBI Pilot cohort. Incomplete recovery was defined as having either post-concussive syndrome or a Glasgow Outcome Scale Extended score <8 at 6 months. Median day-of-injury BDNF concentrations (ng/mL) were lower among TBI cases ( JHH TBI, 17.5 and SFGH TBI, 13.8) than in JHH controls (60.3; p = 0.0001). Among TRACK-TBI Pilot subjects, median BDNF concentrations (ng/mL) were higher in mild (8.3) than in moderate (4.3) or severe TBI (4.0; p = 0.004. In the TRACK-TBI cohort, the 75 (71.4%) subjects with very low BDNF values (i.e.,

show abstract

Section: Diagnostic and Prognostic Value Of Bdnf In Tbimentioning

confidence: 99%

mentioning

confidence: 99%

Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury

Korley

Yue

et al. 2016

Journal of Neurotrauma

115

View full text Add to dashboard Cite

show abstract

“…Together with clinical assessment, the quantitative evaluation of neuronal biomarkers measured within 24 h from either cerebrospinal fluid (CSF) and/or blood could assist in the determination of injury severity, provide specifics to anatomical and cellular pathology of the injury, and could alter clinical management. Although there are a number of biochemical markers that have been investigated in TBI, the most extensively studied among these are glial protein S-100 beta (b) [6][7][8][9][10][11][12][13][14][15][16], neuron-specific enolase (NSE) [17][18][19][20][21][22], and myelin basic protein (MBP) [20,[23][24][25][26] Other promising biomarkers include alpha-II-spectrin breakdown products [27][28][29][30], Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) [31][32][33][34], and microtubule-associated protein (MAP-2) [35].…”

Section: Introductionmentioning

confidence: 99%

Biomarkers Improve Clinical Outcome Predictors of Mortality Following Non-Penetrating Severe Traumatic Brain Injury

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…MAP2 is generally dendrite-specific and potentially a good candidate biomarker for dendritic injury (Kobeissy et al, 2008). A study of 16 patients with severe traumatic brain injury found that serum MAP2 concentrations correlated with neurologic outcome at 6 months after injury (Mondello et al, 2012c). Perinatal asphyxia has been shown to affect the distribution of MAP2 in the brainstem of children (Covenas et al, 2014).…”

Section: Microtubule-associated Protein 2 (Map2)mentioning

confidence: 99%

Blood biomarkers for evaluation of perinatal encephalopathy: state of the art

Graham

Everett

Delpech

et al. 2018

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Recent research in identification of brain injury after trauma shows many possible blood biomarkers that may help identify the fetus and neonate with encephalopathy. Traumatic brain injury shares many common features with perinatal hypoxic-ischemic encephalopathy. Trauma has a hypoxic component, and one of the 1st physiologic consequences of moderate-severe traumatic brain injury is apnea. Trauma and hypoxia-ischemia initiate an excitotoxic cascade and free radical injury followed by the inflammatory cascade, producing injury in neurons, glial cells and white matter. Increased excitatory amino acids, lipid peroxidation products, and alteration in microRNAs and inflammatory markers are common to both traumatic brain injury and perinatal encephalopathy. The blood-brain barrier is disrupted in both leading to egress of substances normally only found in the central nervous system. Brain exosomes may represent ideal biomarker containers, as RNA and protein transported within the vesicles are protected from enzymatic degradation. Evaluation of fetal or neonatal brain derived exosomes that cross the blood-brain barrier and circulate peripherally has been referred to as the "liquid brain biopsy." A multiplex of serum biomarkers could improve upon the current imprecise methods of identifying fetal and neonatal brain injury such as fetal heart rate abnormalities, meconium, cord gases at delivery, and Apgar scores. Quantitative biomarker measurements of perinatal brain injury and recovery could lead to operative delivery only in the presence of significant fetal risk, triage to appropriate therapy after birth and measure the effectiveness of treatment.

show abstract

Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury

Cited by 54 publications

References 33 publications

Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury

Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury

Biomarkers Improve Clinical Outcome Predictors of Mortality Following Non-Penetrating Severe Traumatic Brain Injury

Blood biomarkers for evaluation of perinatal encephalopathy: state of the art

Contact Info

Product

Resources

About